Skip to content

Effect of transcranial magnetic stimulation combined with remimazolam on postoperative recovery quality in elderly patients undergoing hip surgery: A prospective, randomized, double-blind controlled study.

Effect of transcranial magnetic stimulation combined with remimazolam on postoperative recovery quality in elderly patients undergoing hip surgery: A prospective, randomized, double-blind controlled study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124753
Enrollment
Unknown
Registered
2026-05-17
Start date
2026-05-20
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hip surgery

Interventions

Remimazolam group(RZ):"During anesthetic induction, remimazolam was administered intravenously at a dose of 0.2–0.3 mg/kg. A sham coil (D70 Air Film Coil, Magstim) was placed over the left DLPFC while
Transcranial Magnetic Stimulation group(TMS):"Upon tracheal extubation in the PACU, transcranial magnetic stimulation (TMS) was applied to the patients. High-frequency TMS (10 Hz) was delivered to the
Transcranial magnetic stimulation plus remimazolam group (TMS + RZ group):"During anesthetic induction, remimazolam was administered intravenously at a dose of 0.2–0.3 mg/kg. Immediately after trachea

Sponsors

The First Affiliated Hospital of Bengbu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Undergoing elective hip surgery; 2.No gender restriction, aged 60 years or older; 3.Written informed consent obtained from the patients and their families; 4.Assessed as able to tolerate general anesthesia.

Exclusion criteria

Exclusion criteria: 1.Refusal to sign informed consent; 2.Pre-existing mental disorders, psychological disorders, neurocognitive disorders, or a history of central nervous system diseases; 3.Visual or hearing impairment, or communication difficulties; 4.Skull or scalp injury; 5.Drug or alcohol abuse; 6.Presence of metallic implants, cardiac pacemaker, or cochlear implant; 7.Severe cardiovascular or cerebrovascular disease; 8.Mini-Mental State Examination (MMSE) score (range: 0–30, with lower scores indicating worse cognitive function) below 15; 9.Allergy to remimazolam; 10.Other conditions deemed unsuitable for participation by the investigator or attending physician.

Design outcomes

Primary

MeasureTime frame
Quality of Recovery-15 (QoR-15) on postoperative days 1, 2, and 3;

Secondary

MeasureTime frame
Pain score;Incidence of POD;Postoperative complications;

Countries

China

Contacts

Public ContactCongli Zhang

The First Affiliated Hospital of Bengbu Medical College

byfy1010@163.com+86 180 5526 9860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026